@article{JTD14548,
author = {James E. Bates and Michael T. Milano},
title = {Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {7},
year = {2017},
keywords = {},
abstract = {Background: Metastatic non-small cell lung cancer (NSCLC) continues to have a poor prognosis despite recent advances in both targeted radiotherapy methodologies such as stereotactic body radiotherapy (SBRT) and im-munotherapies. The impact of location of metastatic disease in patients with NSCLC has not been investigated; we aimed to investigate this using the Surveillance, Epide-miology, and End Results (SEER) database.
Methods: We included 39,910 patients from the SEER da-tabase treated for M1b NSCLC from 2010–2013. We identified patients with meta-static disease in the brain, lung, liver, and bone. We used Kaplan-Meier analyses and Cox proportional hazards models to assess the impact of varying sites of metastatic disease on overall survival (OS).
Results: Patients with disease coded as in the brain without other disease in the lung, liver, or bone had improved OS relative to all other comers with M1b disease (HR =0.84, 95% CI, 0.84–0.90, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/14548}
}